Non-Invasive Preeclampsia Screening and Biobank

NCT06643741 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 6550

Last updated 2026-01-23

No results posted yet for this study

Summary

Women pregnant between 11-14 weeks gestation will be enrolled with blood samples collected to evaluate for preeclampsia.

Conditions

  • Preeclampsia (PE)

Sponsors & Collaborators

  • Rutgers Robert Wood Johnson Medical School

    collaborator OTHER
  • Laboratory Corporation of America

    collaborator INDUSTRY
  • Sequenom, Inc.

    lead INDUSTRY

Principal Investigators

  • Emily Rosenfeld, DO · Rutgers Robert Wood Johnson Medical School

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-02
Primary Completion
2026-06-01
Completion
2026-07-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06643741 on ClinicalTrials.gov